Is SGMT (Sagimet Biosciences Inc.) Halal or Haram?

Based on our AAOIFI-standard shariah screening, SGMT is classified as Doubtful. It passed 3 of 4 compliance screens. Some scholars may permit investing with income purification, while others advise avoiding it. We recommend consulting a qualified Islamic scholar before investing in SGMT.

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing FASN inhibitors to treat diseases linked to dysfunctional lipid metabolism. Its lead drug candidate, Denifanstat, targets nonalcoholic steatohepatitis (NASH) and acne, while another compound, TVB-3567, is being developed for various cancers. For Muslim investors, SGMT currently holds a Doubtful shariah compliance status based on AAOIFI standards. While the company's core biotechnology operations are fully permissible, it fails the liquidity screen due to its high cash reserves relative to its market capitalization, meaning investors cannot currently add it to a strict halal portfolio. From an Islamic finance perspective, Sagimet boasts excellent leverage metrics, carrying 0.0% debt to market cap and generating 0.00% impermissible interest income. However, its cash and securities ratio sits at an elevated 40.2%, breaching the strict 33% threshold allowed to ensure a company is not trading primarily as a liquid asset. Because clinical-stage biotech firms often hold large cash reserves to fund ongoing trials before generating product revenue, this liquidity breach is common in the sector. Halal investors should monitor the stock's market valuation, as an increase in share price could naturally bring the cash-to-market-cap ratio back into compliant territory. Sagimet Biosciences Inc. operates in the Healthcare sector under the Biotechnology industry and is headquartered in San Mateo, CA, US. The company is led by CEO David A. Happel and employs approximately 14 people.

SGMT was screened using AAOIFI-based shariah compliance criteria. Four tests are applied: (1) Business Activity — the company's core business must not derive primary income from haram (prohibited) activities such as alcohol, gambling, tobacco, or interest-based finance. (2) Debt-to-Market-Cap — total debt must not exceed 33% of market capitalization. (3) Interest Income — interest income must not exceed 5% of total revenue. (4) Cash & Securities — cash and interest-bearing securities must not exceed 33% of market cap. SGMT passed 3 of these 4 screens.

SGMT was last screened on 2026-04-27. Shariah compliance status can change as companies report new financial data, acquire new businesses, or shift revenue streams. We recommend checking back periodically for the most up-to-date screening results.